|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 20-F filed Feb 26, 2009. Maxipime
We licensed the U.S. marketing rights to Maxipime
from Bristol-Myers in January 1999. Maxipime is a
fourth-generation injectable cephalosporin antibiotic used to
treat patients with serious
and/or
life-threatening infections.
For 2008, revenue from Maxipime decreased 78% to
$27.1 million from $122.5 million for 2007,
principally due to generic competition. The first generic
cefepime hydrochloride was launched in June 2007, and additional
generic forms of Maxipime have since been launched.
This excerpt taken from the ELN 20-F filed Feb 28, 2008. Maxipime
We licensed the U.S. marketing rights to Maxipime
from Bristol-Myers Squibb Company (Bristol-Myers) in January
1999. Maxipime is a fourth-generation injectable
cephalosporin antibiotic used to treat patients with serious
and/or
life-threatening infections. Revenue from sales of Maxipime
totaled $122.5 million for 2007 (2006:
$159.9 million). The basic U.S. patent on Maxipime
expired in March 2007. On June 18, 2007, the first
generic formulation of cefepime hydrochloride was approved by
the FDA. Generic cefepime hydrochloride has, and we
Table of Contents
expect it will continue to, materially and adversely affect our
revenues from, and gross margin for, Maxipime. While
Maxipime is available through distributors, we no longer
promote this product.
This excerpt taken from the ELN 20-F filed Feb 28, 2007. Maxipime
We licensed the US marketing rights to Maxipime from
Bristol-Myers Squibb Company (Bristol-Myers) in January 1999.
Maxipime is a fourth-generation injectable cephalosporin
antibiotic used to treat patients with serious
and/or
life-threatening infections. Pulmonologists, infectious disease
specialists, emergency medicine specialists, surgeons, internal
medicine physicians, hematologists and oncologists prescribe
Maxipime for patients with severe infections requiring
hospitalization, such as pneumonia, urinary tract infection and
febrile neutropenia. Attributes of Maxipime are its broad
spectrum of activity, including activity against many pathogens
resistant to other antibiotics, ease of use and favorable
pharmaco-economic profile. Revenue from sales of Maxipime
totaled
Table of Contents
$159.9 million for 2006 (2005: $140.3 million). The
basic US patent on Maxipime expires in March 2007. Two
other US patents covering Maxipime formulations expire in
February 2008.
This excerpt taken from the ELN 20-F filed Mar 30, 2006. Maxipime
We licensed the U.S. marketing rights to Maxipime
from Bristol-Myers Squibb Company (Bristol-Myers) in January
1999. Maxipime is a fourth-generation injectable
cephalosporin antibiotic used to treat patients with serious
and/or
life-threatening infections. Pulmonologists, infectious disease
specialists, emergency medicine specialists, surgeons, internal
medicine physicians, hematologists and oncologists prescribe
Maxipime for patients with severe infections requiring
hospitalization, such as pneumonia, urinary tract infection and
febrile neutropenia. Attributes of Maxipime are its broad
spectrum of activity, including activity against many pathogens
resistant to other antibiotics, ease of use and favorable
pharmaco-economic profile. Revenue from sales of Maxipime
amounted to $140.3 million for 2005. The basic
U.S. patent on Maxipime expires in March 2007.
However, two other U.S. patents covering Maxipime
formulations may provide protection until February 2008.
| EXCERPTS ON THIS PAGE:
|
| |||||||
